Terapias con Hormonas Bioidéntica, Referencias

Terapias con Hormonas Bioidénticas

1. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11:356-67.

2. MacLennan AH, Sturdee DW. The ‘bioidentical/bioequivalent’ hormone scam. Climacteric 2006;9:1-3.

3. The Endocrine Society: Position Statement: Bioidentical Hormones, October 2006: http://www.endosociety.org

4. Huntley AL. Compounded or confused? Bioidentical hormones and menopausal health. Menopause Int 2011;17:16-18.

5. Schmidt P. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19:257-71.

6. Compounded bioidentical menopausal hormone therapy. Committee Opinion No. 532. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:411-15.

7. de Villers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2013;16:203-4.

Síntomas Vasomotores: THM y Tratamientos Farmacológicos

1. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-7.

2. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71.

3. Rada G, Capurro D, Pantoja T, et al. Nonhormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;(9):CD004923 78.

4. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010;8:1171-9.

5. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-63.

6. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.

7. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.

8. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-6.

9. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-30.

10. Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008;15:655-60.

11. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-83.

12. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-74.

13. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-45.

14. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised doubleblind placebo-controlled trial. Lancet 2005;366:818-24.

15. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-90.

16. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-8.

17. Joffe H, Guthrie KA, LaCroix AZ, et al. Lowdose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058-66.

18. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-52.

19. Suvanto-Luukkonen E, Koivunen R, Sundström H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebocontrolled, double-blind study. Menopause 2005;12:18-26.

20. Kerwin JP, Gordon PR, Senf JH. The variableresponse of women with menopausal hot flashes when treated with sertraline. Menopause 2007;14:841-5.

21. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823-30.

22. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 2009;16:477-83 79.

23. Jin Y, Desta Z, Stearns V, et al. CYP2D6genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.

24. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receivingtamoxifen: a population based cohort study. BMJ 2010;340:c693.

25. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Brosen K. Escitalopram is a weak inhibitor of the CYP2D6- catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 2009;86:626-33.

26. Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen’s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. J Cancer 2008;99:616–21.

Atrofia Vulvovaginal Posmenopáusica

1. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric 2014;17:557-63.

2. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 2012;15:36-44.

3. Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) Survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232-41.

4. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194-203.

5. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18: 121-34.

6. Simon JA, Maamari RV. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric 2013;16(Suppl 1):37-43.

7. Suckling J, Kennedy R, Lethaby A, Roberts H. Local estrogen therapy for vaginal atrophy in post menopausal women. Cochrane Database Syst Rev 2006 Issue 4 CD 001500.

8. Sturdee DW, Panay N, on behalf of the IMS Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22.

9. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015;18:226-32.

10. Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning. J Sex Med 2009;6:603-16.

11. Nappi RE, Panay N, Bruyniks N, Castelo- Branco C, de Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233-40.

12. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 2014;142:142-54.

13. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91-8, 80.

14. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-todate overview. Climacteric 2013;16:305-12.

Nuevas Terapias para la Menopausia

1. Archer DF, Labrie F, Bouchard C, et al.; other participating members of the VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950-63.

2. Bouchard C, Labrie F, Archer DF, et al.; VVA Prasterone Group. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric 2015;18:590-607.

3. Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, de Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233-40 .

4. Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric 2013;16:618-28.

5. Smith CL, Santen RJ, Komm B, Mirkin S. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res 2014;16:212.

* Correspondencia: Profesor R. J. Baber, Obstetrics and Gynaecology, Sydney Medical School North, The University of Sydney, Sydney, Australia; email: rod@rodbaber.com.au(c) 2016 Sociedad Internacional de Menopausia.
** Colaboradores de esta versión en español.